Management of Small Renal Masses
- An improved understanding of the natural history of SRMs underscores their overall slow growth rate and low propensity to metastasize.
- Up to 30% of SRMs are benign, highlighting a role for upfront renal tumor biopsy to stratify those patients requiring therapy. Contemporary experience has demonstrated the safety in performing renal tumor biopsy and the excellent diagnostic rates (> 90%) that can be achieved at centers of excellence.
- There is an increasing role for active surveillance for SRMs, with appropriately selected patients achieving excellent clinical outcomes.
- Partial nephrectomy remains the gold standard treatment for SRMs requiring intervention when technically feasible.
- The management of SRMs is evolving towards a personalized medicine approach with integration of clinical nomograms and genomics to better predict which patients require treatment and when.